| titleOfInvention |
antibody or antigen-binding fragment thereof, antibody or an antigen-binding fragment that specifically bind to a human cd25 epotype, affinity-matured variant of an antibody or its antigen-binding fragment, nucleic acid molecule, vector nucleic acid, host cell, method for producing an antibody or antigen-binding fragment thereof, pharmaceutical composition, use of an antibody or antigen-binding fragment thereof, method for treating cancer in an individual, method for depleting t cells regulators in a tumor in an individual, antibody or antigen-binding fragment that competes with an antibody, kit, method for preparing an anti-cd25 antibody and method for preparing a pharmaceutical composition |
| abstract |
antibody or antigen-binding fragment thereof, antibody or an antigen-binding fragment that specifically bind to a human cd25 epotype, affinity-matured variant of an antibody or its antigen-binding fragment, nucleic acid molecule, vector nucleic acid, host cell, method for producing an antibody or antigen-binding fragment thereof, pharmaceutical composition, use of an antibody or antigen-binding fragment thereof, method for treating cancer in an individual, method for depleting t cells regulatory factors in a tumor in an individual, antibody or antigen-binding fragment that competes with an antibody, kit, method for preparing an anti-cd25 antibody and method for preparing a pharmaceutical composition. the present disclosure provides antibody sequences found in antibodies that bind to human cd25. in particular, the present disclosure provides sequences of anti-human cd25 antibodies, which do not block the binding of cd25 to the il-2 or il-2 signaling. antibodies and antigen-binding portions thereof that include such sequences can be used in pharmaceutical composition and treatment methods, in particular to treat cancer. |